DelveInsight’s ‘Frontotemporal Dementia Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline frontotemporal dementia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the frontotemporal dementia pipeline domain.
For frontotemporal dementia emerging drugs, the frontotemporal dementia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Frontotemporal Dementia (FTD) Pipeline Report
- Over 20+ frontotemporal dementia pipeline therapies are in various stages of development, and their anticipated acceptance in the frontotemporal dementia market would significantly increase market revenue.
- Leading frontotemporal dementia companies developing novel drug candidates to improve the frontotemporal dementia treatment landscape include Alector, Prevail Therapeutics, Passage Bio, Inc., Wave Life Sciences Ltd., CAMP4 Therapeutics, Coya Therapeutics, SOLA Biosciences, AcuraStem, Denali Therapeutics, Neurimmune, Biogen, Asceneuron SA, Libra Therapeutics, Muna Therapeutics, Alkermes, DEEP GENOMICS, Sangamo Therapeutics, LOCANABIO, Arkuda Therapeutics, Yumanity, Autifony Therapeutics, Prothena, Mabylon AG, and others.
- Promising frontotemporal dementia pipeline therapies in various stages of development include AL001, TPN-101, PBFT02, PR006, DNL593 (PTV: PRGN), Research programme: CNS therapeutics, NI308, Research Programme: M1 PAM, AS-203, WVE-004, COYA 102, SOL-257, and others.
- Among the frontotemporal dementia pipeline therapies, AL001 by Alector is in the late stage of development.
- In February 2022, Arkuda Therapeutics, announced the completion of a $64 million Series B financing. The financing was co-led by Cormorant Asset Management and Pivotal bioVenture Partners, with participation from Surveyor Capital (a Citadel company), and Eli Lilly and Company, as well as existing investors Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and Mission BioCapital.
- In January 2022, The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced that they have partnered to support Wave Life Sciences’ FOCUS-C9 Phase 1b/2a clinical trial investigating WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD), as well as amyotrophic lateral sclerosis (C9-ALS).
Request a sample and discover the recent breakthroughs happening FTD pipeline landscape in @ Frontotemporal Dementia Pipeline Report
Frontotemporal Dementia Overview
Frontotemporal Dementia (FTD) is a group of disorders caused by progressive degeneration of the brain’s frontal and temporal lobes. The most common signs and symptoms of Frontotemporal Dementia are changes in behavior, language, and decision-making abilities. FTD is a type of young-onset dementia that affects people aged 45 to 65. It is the most common type of dementia in people under the age of 60. People in the final stages of frontotemporal dementia cannot care for themselves. Clinical symptoms are comparable to those seen in other dementias or psychiatric disorders. From the onset of frontotemporal dementia symptoms to a correct diagnosis, it takes an average of 3.6 years.
The main causes of frontotemporal dementia are unknown, but they are thought to be genetic, as 1 in every 8 people with this condition has a family history of it.
Find out more facts about frontotemporal dementia @ Frontotemporal Dementia Posture
Frontotemporal Dementia Pipeline Analysis: Drug Profile
PR 006: Prevail Therapeutics
PR006 is being developed as a single-dose, potentially disease-modifying gene therapy for patients with frontotemporal dementia who have GRN mutations (FTD-GRN). PR006 is intended to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via central nervous system delivery of a healthy GRN gene (CNS).
Latozinemab: Alector
AL001 inhibits progranulin (PGRN), a key regulator of immune activity in the brain that has been linked to a number of neurodegenerative disorders. AL001 is being developed initially for frontotemporal dementia (FTD) with a progranulin mutation (FTD-GRN). The global INFRONT-3 Phase III clinical trial is currently enrolling participants with FTD-GRN who are both at risk and symptomatic. AL001 is being developed in partnership with GSK.
Frontotemporal Dementia Pipeline Therapies and Key Companies
- AL001: Alector IncTPN-101: Transposon Therapeutics
- PBFT02: Passage Bio, Inc.
- PR006: Prevail Therapeutics
- DNL593(PTV:PRGN): Denali Therapeutics Inc.
- NI308: Neurimmune
- Research programme: CNS therapeutics: CAMP4 Therapeutics
- Research Programme: M1 PAM: Asceneuron SA
- AS-203: AcuraStem
Learn more about the FTD emerging pipeline therapies @Frontotemporal Dementia Clinical Trials
Frontotemporal Dementia Pipeline Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Intravenous
- Inhalation
- Subcutaneous
- By Molecule Type
- Gene therapy
- Stem cell therapy
- Small molecules
Scope of the Frontotemporal Dementia Pipeline Report
- Coverage: Global
- Key Frontotemporal Dementia Companies: Alector (NASDAQ: ALEC), Prevail Therapeutics, Passage Bio, Inc. (NASDAQ: PASG), Wave Life Sciences Ltd. (NASDAQ: WVE), CAMP4 Therapeutics, Coya Therapeutics, SOLA Biosciences, AcuraStem, Denali Therapeutics (NASDAQ: DNLI), Neurimmune, Biogen (NASDAQ: BIIB), Asceneuron SA, Libra Therapeutics, Muna Therapeutics, Alkermes (NASDAQ: ALKS), DEEP GENOMICS, Sangamo Therapeutics (NASDAQ: SGMO), LOCANABIO, Arkuda Therapeutics, Yumanity (NASDAQ: YMTX), Autifony Therapeutics, Prothena (NASDAQ: PRTA), Mabylon AG, and others.
- Key Frontotemporal Dementia Pipeline Therapies: AL001, TPN-101, PBFT02, PR006, DNL593(PTV: PRGN), Research programme: CNS therapeutics, NI308, Research Programme: M1 PAM, AS-203, WVE-004, COYA 102, SOL-257, and others.
Dive deep into rich insights for emerging therapies and assessment, visit @ Frontotemporal Dementia Emerging Therapies
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Overview |
| 4. | Pipeline Therapeutics |
| 5. | Late Stage Products (Phase III) |
| 6. | Mid Stage Products (Phase II) |
| 7. | Early Stage Products (Phase I/II) |
| 8. | Preclinical Stage Products |
| 9. | Discovery Stage Products |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Collaborations Assessment- Licensing / Partnering / Funding |
| 13. | Unmet Needs |
| 14. | Market Drivers and Barriers |
| 15. | Appendix |
| 16. | About DelveInsight |
For further information on the Frontotemporal Dementia current pipeline therapeutics, reach out @ Frontotemporal Dementia Ongoing Clinical Trials
Related Reports
Frontotemporal Dementia Market
Frontotemporal Dementia Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the indication, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers and key Frontotemporal Dementia companies, involved such as TauRx Therapeutics Ltd., Alector, Axon Neuroscience, Passage Bio, Wave Life Sciences, among others.
Dementia with Diabetes Pipeline
Dementia with Diabetes Pipeline Insight, 2022 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Dementia with Diabetes companies involved such as vTv Therapeutics, among others.
Vascular Dementia Pipeline Insight, 2022 report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Vascular Dementia companies involved such as Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, among others.
Lewy Body Dementia Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Lewy Body Dementia companies involved such as Eisai, Sun Pharma, among others.
AIDS Dementia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the AIDS Dementia, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AIDS Dementia companies involved such as BMS, NIAID, Glaxo Wellcome, Beau Nakamoto, among others.
Dementia Associated With Alzheimer’s Disease Pipeline
Dementia Associated With Alzheimer’s Disease Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Dementia Associated With Alzheimer’s Disease companies involved such as Ortho-McNeil Neurologics, Sunnybrook Health Sciences Centre, Otsuka Pharmaceutical, Solvay Pharmaceuticals, Helse Stavanger HF, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Hemophilia A Market | Hemostasis Market | Peptic Ulcers Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187